Biogen Price Targed Raised After Positive Data Report and 4 Stock Analyses to Note

Veeco Instruments Inc. (NASDAQ:VECO):  Lazard Capital believes that any meaningful recovery for the MOCVD tool market will not occur until the second half of 2013 at the earliest. The firm lowered their estimates for Veeco Instruments Inc. and Aixtron (NASDAQ:AIXG) to reflect their continued caution regarding the sector. They lowered their 2013 tool estimate from 365 to 345.

Bristol-Myers Squibb Company (NYSE:BMY):  BMO Capital said that Bristol-Myers Squibb Company and Pfizer (NYSE:PFE) announced the resubmission for Eliquis. The Federal Drug Administration assigned a March 17, 2013 Prescription Drug User Fee Act (PDUFA). The firm said that the resubmission was on time and that an early approval before the PDUFA is probable. Shares of  Bristol-Myers are Outperform rated.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Biogen Idec Inc. (NASDAQ:BIIB):  Citing the company’s positive Phase 3 Hemophilia data, Jefferies raised their price target for Biogen Idec Inc.  The firm keeps a Buy rating on the stock.

Time Warner Cable Inc. (NYSE:TWC):  Canaccord rolled out their 2013 valuation on Buy rated Time Warner and believes the company has attractive fundamentals and capital allocation for their shareholders.

Comcast Corporation (NASDAQ:CMCSA):  Due to higher ratings and the sell-out rate of the Summer Olympics, Canaccord increased their adjusted operating cash flow for NBC. Shares are Buy rated.

Don’t Miss: Here’s General Electric’s Big New Deal.